Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
16°
Clear
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aura Biosciences Inc
(NQ:
AURA
)
9.030
+0.280 (+3.20%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Aura Biosciences Inc
< Previous
1
2
Next >
Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease
October 18, 2024
Aura Biosciences released early Phase 1 trial data on bel-sar for non-muscle-invasive bladder cancer, showing promising clinical activity and a favorable safety profile.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
October 17, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
October 14, 2024
Via
Benzinga
Aura Biosciences Touts Promising Data From Eye Cancer Candidate
September 12, 2024
Aura Biosciences announced promising Phase 2 results for bel-sar in treating melanoma, achieving 80% tumor control.
Via
Benzinga
AURA Stock Earnings: Aura Biosciences Beats EPS for Q2 2024
August 08, 2024
AURA stock results show that Aura Biosciences beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Recap: Aura Biosciences Q4 Earnings
March 27, 2024
Via
Benzinga
Recap: Aura Biosciences Q1 Earnings
May 11, 2023
Via
Benzinga
Aura Biosciences Releases Data Presentation Of Eye Cancer Candidate
February 16, 2023
Via
Benzinga
Why Shares of Aura Biosciences Jumped This Week
February 10, 2023
The clinical-stage biotech may be ready to release updated phase 3 trial results on its lead therapy.
Via
The Motley Fool
AURA Stock Earnings: Aura Biosciences Beats EPS for Q1 2024
May 09, 2024
AURA stock results show that Aura Biosciences beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
AURA Stock Earnings: Aura Biosciences Beats EPS for Q4 2023
March 27, 2024
AURA stock results show that Aura Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
January 09, 2024
Via
Benzinga
Over $13M Bet On This Energy Stock? Check Out These 4 Stocks Insiders Are Buying
November 10, 2023
Although U.S. stocks closed lower on Thursday, there were a few notable insider trades.
Via
Benzinga
Why Aura Biosciences Stock Hit A New 52-Week Low Today
November 07, 2023
Aura Biosciences Inc (NASDAQ: AURA) shares are trading lower by 34.7% to $7.18 Tuesday afternoon after the company announced pricing of its public offering of common st
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
November 07, 2023
Via
Benzinga
Aura Biosciences Details Interim Data From Mid-Stage Study Of Ocular Oncology Drug
October 03, 2022
Via
Benzinga
Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
November 07, 2023
Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry.
Via
Benzinga
Why Alteryx Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
November 07, 2023
Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares surged 120.8% to $0.6450 in pre-market trading after the company reported a new strategic collaboration with Celest Therapeutics for the clinical...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
November 07, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
November 07, 2023
It's time for another dive into the biggest pre-market stock movers as we break down all of the latest news for Tuesday morning.
Via
InvestorPlace
Sanmina, Adtran, Ameresco And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
November 07, 2023
U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
November 06, 2023
Via
Benzinga
Top 5 Health Care Stocks That May Fall Off A Cliff This Month
November 06, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023
July 27, 2023
Via
Benzinga
$49.5 Million Bet On Howard Hughes? Check Out These 4 Stocks Insiders Are Buying
December 08, 2022
Although US stocks closed mostly lower on Wednesday, there were a few notable insider trades.
Via
Benzinga
Why Dollar General Shares Are Trading Lower By Over 8%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session
December 01, 2022
Gainers Top Ships Inc. (NASDAQ: TOPS) shares jumped 74% to $5.24. Vapotherm, Inc. (NASDAQ: VAPO) gained 48.8% to $1.3250.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
December 01, 2022
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 01, 2022
Via
Benzinga
Tesla, ABB And Other Big Losers From Monday
October 04, 2022
U.S. stocks closed sharply higher with the Dow Jones jumping more than 750 points on Monday. Here is the list of some big stocks recording losses in the previous session.
Via
Benzinga
Why Oil-Related Stocks Traded Higher; Here Are 74 Biggest Movers From Yesterday
October 04, 2022
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per...
Via
Benzinga
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.